Board-Certified Oncologist & Hematologist in Tacoma, Federal Way & Gig Harbor, WA
“What does it mean to be an oncologist? It means that you are privileged to sit in at a moment of another person’s life that is hyper-acute, and not just because he/she is medically ill. It is also a moment of hope, expectation and concern.’ My passion is to use solid scientific knowledge to guide patients through the most difficult time in their lives, to achieve the best possible oncological outcome, as well as a peace of mind.” – Li Zhang, MD
Dr. Zhang is a Medical Oncologist & Hematologist specializing in GU malignancies (prostate, bladder, kidney, and testicular cancers), lung cancers, and cutaneous malignancies.
She completed her fellowship at the Dana-Farber Cancer Institute at St. Elizabeth Medical Center, working with leaders in GU oncology and presented research at the 2018 ASCO Annual Meeting. Her publications include work in JAMA Network Open and Prostate Cancer and Prostatic Diseases.
Dr. Zhang has served as a GU medical oncologist at Geisinger Medical Center, led immunotherapy toxicity management initiatives, created a Molecular Tumor Board in collaboration with Foundation Medicine, and mentored fellows on ASCO presentations. She currently leads the CHI GU Tumor Board, is a core member of the ONCare GU cancer pathways team and is a frequent presenter at Best of ASCO as well as other oncology conferences.
Outside of medicine, Dr. Zhang enjoys gardening, cooking, hiking, and traveling with her family.
Medical School:
Southeast University Medical College, Nanjing, China
Chinese PLA Postgraduate Medical School, Beijing, China
Residency: St. Agnes Hospital, Baltimore, MD – Internal Medicine
Fellowship: Dana-Farber Cancer Institute at St. Elizabeth Medical Center, Brighton, MA – Hematology, Oncology
Board Certifications: Medical Oncology, Hematology, Internal Medicine
Peer-Reviewed Publications:
1. Francini E, Zhang L, Sweeney C, et al. Association of concomitant bone resorption inhibitors with overall survival among patients with metastatic castration-resistant prostate cancer and bone metastases receiving abiraterone acetate with prednisone as first-line therapy. JAMA Network Open. July 2021; 4(7): e2116536.
2. McGregor B, Zhang L, Sweeney C, et al. Bone targeted therapy and skeletal related events in the era of enzalutamide and abiraterone acetate for castration resistant prostate cancer with bone metastases. Prostate Cancer Prostatic Dis. Jun 2021; 24(2): 341-348.
3. Makary M, Zhang L (as contact author), et al. Single-institution experience of small cell bladder cancer at a community center. 2020 ASCO Abstract.